Corpus ID: 26708976

Freireich's laws in the treatment of sarcomas.

@article{Benjamin1997FreireichsLI,
  title={Freireich's laws in the treatment of sarcomas.},
  author={R. Benjamin},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 12 Pt 2},
  pages={
          2648-54
        }
}
  • R. Benjamin
  • Published 1997
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
In his Karnofsky lecture of May 6, 1976, Dr. Emil J Freireich formalized seven of his multiple laws ( 1 ). Although this manuscript will not deal with law 7, the Regulators Creed, laws 1-6 are relevant to the treatment of sarcomas (Table 1), and I shall address several areas emphasized by Dr. Freireich in that lecture: optimism, expertise, the importance of dose, and the need for individualized therapy. The first area is optimism. In his Kamofsky lecture, Dr. Freireich said, “If the clinical… Expand
2 Citations
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89)
  • 5
Summary of the first Emil J Freireich symposium.
  • R. Bast
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
  • PDF

References

SHOWING 1-10 OF 46 REFERENCES
Who took the clinical out of clinical research?--Mouse versus man: seventh David A Karnofsky Memorial Lecture--1976.
  • E. Freireich
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
  • 14
  • Highly Influential
  • PDF
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  • A. Santoro, T. Tursz, +7 authors E. Rankin
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
  • 471
  • Highly Influential
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
  • 249
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
  • K. Antman, J. Crowley, +7 authors D. Trump
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
  • 423
...
1
2
3
4
5
...